Literature DB >> 20837833

Type 1 Gaucher disease: significant disease manifestations in "asymptomatic" homozygotes.

Manisha Balwani1, Laura Fuerstman, Ruth Kornreich, Lisa Edelmann, Robert J Desnick.   

Abstract

BACKGROUND: Type 1 Gaucher disease (GD), an autosomal recessive lysosomal storage disease, is most prevalent in the Ashkenazi Jewish (AJ) population. Experts have suggested that up to two-thirds of AJ homozygotes for the common mutation (N370S) are asymptomatic throughout life and never come to medical attention. However, there are no systematic studies of N370S homozygotes to support this presumption.
METHODS: Prenatal carrier screening of 8069 AJ adults for 6 common GD mutations was performed. Gaucher disease manifestations in 37 previously unrecognized homozygotes were assessed by clinical, laboratory, and imaging studies.
RESULTS: Among the 8069 AJ screenees, 524 GD carriers (1:15) and 9 previously unrecognized GD homozygotes (1:897) were identified, consistent with the rate expected (1:949; P > .99). Six of these homozygotes and 31 AJ GD homozygotes identified by other prenatal carrier screening programs in the New York City metropolitan area were evaluated (age range of the homozygotes, 17-40 years). Of these, 84% were N370S homozygotes, others being heteroallelic for N370S and V394L, L444P, or R496H mutations. Notably, 65% reported no GD medical complaints. However, 49% had anemia and/or thrombocytopenia. Among the 29 who had imaging studies, 97% had mild to moderate splenomegaly and 55% had hepatomegaly; skeletal imaging revealed marrow infiltration (100%), Erlenmeyer flask deformities (43%), lucencies (22%), and bone infarcts (14%). Dual energy X-ray absorptiometry studies of 25 homozygotes found 60% with osteopenia or osteoporosis.
CONCLUSION: Contrary to previous discussions, almost all asymptomatic GD homozygotes serendipitously diagnosed by prenatal carrier screening had disease manifestations and should be followed for disease progression and institution of appropriate medical treatment.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20837833      PMCID: PMC3098047          DOI: 10.1001/archinternmed.2010.302

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  38 in total

1.  High frequency of the Gaucher disease mutation at nucleotide 1226 among Ashkenazi Jews.

Authors:  A Zimran; T Gelbart; B Westwood; G A Grabowski; E Beutler
Journal:  Am J Hum Genet       Date:  1991-10       Impact factor: 11.025

Review 2.  Gaucher disease: new molecular approaches to diagnosis and treatment.

Authors:  E Beutler
Journal:  Science       Date:  1992-05-08       Impact factor: 47.728

Review 3.  Gaucher disease: gene frequencies and genotype/phenotype correlations.

Authors:  G A Grabowski
Journal:  Genet Test       Date:  1997

4.  Bone density changes with enzyme therapy for Gaucher disease.

Authors:  Ehud Lebel; Altoon Dweck; A Joseph Foldes; Yosef Golowa; Menachem Itzchaki; Ari Zimran; Deborah Elstein
Journal:  J Bone Miner Metab       Date:  2004       Impact factor: 2.626

5.  Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry.

Authors:  Neal J Weinreb; Joel Charrow; Hans C Andersson; Paige Kaplan; Edwin H Kolodny; Pramod Mistry; Gregory Pastores; Barry E Rosenbloom; C Ronald Scott; Rebecca S Wappner; Ari Zimran
Journal:  Am J Med       Date:  2002-08-01       Impact factor: 4.965

6.  Gaucher disease: gene frequencies in the Ashkenazi Jewish population.

Authors:  E Beutler; N J Nguyen; M W Henneberger; J M Smolec; R A McPherson; C West; T Gelbart
Journal:  Am J Hum Genet       Date:  1993-01       Impact factor: 11.025

Review 7.  Gaucher disease: complexity in a "simple" disorder.

Authors:  Ellen Sidransky
Journal:  Mol Genet Metab       Date:  2004 Sep-Oct       Impact factor: 4.797

8.  Gaucher disease type 1: revised recommendations on evaluations and monitoring for adult patients.

Authors:  Neal J Weinreb; Mario C Aggio; Hans C Andersson; Generoso Andria; Joel Charrow; Joe T R Clarke; Anders Erikson; Pilar Giraldo; Jack Goldblatt; Carla Hollak; Hiroyuki Ida; Paige Kaplan; Edwin H Kolodny; Pramod Mistry; Gregory M Pastores; Ricardo Pires; Ainu Prakash-Cheng; Ainu Prakesh-Cheng; Barry E Rosenbloom; C Ronald Scott; Elisa Sobreira; Anna Tylki-Szymańska; Ashok Vellodi; Stephan vom Dahl; Rebecca S Wappner; Ari Zimran
Journal:  Semin Hematol       Date:  2004-10       Impact factor: 3.851

9.  Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages.

Authors:  Leonie A Boven; Marjan van Meurs; Rolf G Boot; Atul Mehta; Louis Boon; Johannes M Aerts; Jon D Laman
Journal:  Am J Clin Pathol       Date:  2004-09       Impact factor: 2.493

10.  Phenotype/genotype correlations in Gaucher disease type I: clinical and therapeutic implications.

Authors:  A Sibille; C M Eng; S J Kim; G Pastores; G A Grabowski
Journal:  Am J Hum Genet       Date:  1993-06       Impact factor: 11.025

View more
  22 in total

1.  Experience with carrier screening and prenatal diagnosis for 16 Ashkenazi Jewish genetic diseases.

Authors:  Stuart A Scott; Lisa Edelmann; Liu Liu; Minjie Luo; Robert J Desnick; Ruth Kornreich
Journal:  Hum Mutat       Date:  2010-11       Impact factor: 4.878

2.  Connecting Gaucher and Parkinson Disease: Considerations for Clinical and Research Genetic Counseling Settings.

Authors:  Lola Cook; Jeanine Schulze
Journal:  J Genet Couns       Date:  2017-06-30       Impact factor: 2.537

Review 3.  Gaucher disease: the metabolic defect, pathophysiology, phenotypes and natural history.

Authors:  Hagit N Baris; Ian J Cohen; Pramod K Mistry
Journal:  Pediatr Endocrinol Rev       Date:  2014-09

4.  An ACE diagnosis.

Authors:  Omar Nasher; Anindya Gupta
Journal:  BMJ Case Rep       Date:  2013-02-14

Review 5.  Where genotype is not predictive of phenotype: towards an understanding of the molecular basis of reduced penetrance in human inherited disease.

Authors:  David N Cooper; Michael Krawczak; Constantin Polychronakos; Chris Tyler-Smith; Hildegard Kehrer-Sawatzki
Journal:  Hum Genet       Date:  2013-07-03       Impact factor: 4.132

6.  Intra-monocyte Pharmacokinetics of Imiglucerase Supports a Possible Personalized Management of Gaucher Disease Type 1.

Authors:  Juliette Berger; Marie Vigan; Bruno Pereira; Thu Thuy Nguyen; Roseline Froissart; Nadia Belmatoug; Florence Dalbiès; Agathe Masseau; Christian Rose; Christine Serratrice; Yves-Marie Pers; Ivan Bertchansky; Fabrice Camou; Monia Bengherbia; Céline Bourgne; Catherine Caillaud; Magali Pettazzoni; Amina Berrahal; Jérôme Stirnemann; France Mentré; Marc G Berger
Journal:  Clin Pharmacokinet       Date:  2019-04       Impact factor: 6.447

7.  Gaucher disease: when molecular testing and clinical presentation disagree -the novel c.1226A>G(p.N370S)--RecNcil allele.

Authors:  Manisha Balwani; Marie E Grace; Robert J Desnick
Journal:  J Inherit Metab Dis       Date:  2011-03-23       Impact factor: 4.982

8.  Patients' Opinions on Genetic Counseling on the Increased Risk of Parkinson Disease among Gaucher Disease Carriers.

Authors:  Maureen Mulhern; Louise Bier; Roy N Alcalay; Manisha Balwani
Journal:  J Genet Couns       Date:  2017-09-30       Impact factor: 2.537

9.  Early manifestations of type 1 Gaucher disease in presymptomatic children diagnosed after parental carrier screening.

Authors:  Amy C Yang; Louise Bier; Jessica R Overbey; Jessica Cohen-Pfeffer; Khyati Desai; Robert J Desnick; Manisha Balwani
Journal:  Genet Med       Date:  2016-10-13       Impact factor: 8.822

Review 10.  Gaucher disease: Basic and translational science needs for more complete therapy and management.

Authors:  Gregory A Grabowski; Armand H M Antommaria; Edwin H Kolodny; Pramod K Mistry
Journal:  Mol Genet Metab       Date:  2020-12-29       Impact factor: 4.797

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.